ECOR Stock Analysis
EC
Uncovered
electroCore, Inc. is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 62 full-time employees. The company went IPO on 2018-06-22. The company provides non-invasive vagus nerve stimulation (nVNS) technology platform. The company is focused on commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to general wellbeing and human performance in the United States and select overseas markets. nVNS is a platform bioelectronic technology that modulates neurotransmitters through its effects on both the peripheral and central nervous systems. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore device for the treatment of pain associated with each migraine headache and episodic cluster headache in adults, the preventive treatment of migraine headache and adjunctive use for the preventive treatment of cluster headache in adults, the acute and preventive treatment of migraine in adolescents and Paroxysmal Hemicrania, and Hemicrania Continua in adults.